Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies

作者：Yajing Feng, Fujiao Duan, Weigang Liu, Xiaoli Fu, Shuli Cui, Zhenxing Yang · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.17642 · 被引用次数：6 · 研究领域：MicroRNA in disease regulation、Cancer-related molecular mechanisms research、Circular RNAs in diseases

// Yajing Feng 1, 4 , Fujiao Duan 2, 6 , Weigang Liu 3 , Xiaoli Fu 4 , Shuli Cui 5 and Zhenxing Yang 2 1 Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 2 Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China 3 Medical Record Statistics Office, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China 4 College of Public Health, Zhengzhou University, Zhengzhou, Henan, China 5 College of Professional Study, Northeastern University, Boston, Massachusetts, USA 6 Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China Correspondence to: Yajing Feng, email: grglfyj@163.com Fujiao Duan, email: fund@126.com Keywords: miR-214, cancer, prognosis, systematic evaluation Received: February 04, 2017     Accepted: April 07, 2017     Published: May 06, 2017 ABSTRACT Previous studies showed that microRNA-214 (miR-214) may act as a prognostic biomarker of cancer. However, the available evidence is controversial. This study summarizes evidence and evaluates the prognostic role of miR-214 in various cancers. We carried out a systematic literature review and assessed the quality of included studies based on Oxford Centre for Evidence-based Medicine Criteria and Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for overall survival (OS) and disease...